Seeking Alpha
10 Jun 2026, 04:22 UTC · 6h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
2 claims · each scored for market impact
4D Molecular Therapeutics has its leading program, 4D-150 for wet AMD, currently in Phase III trials (4FRONT-1 and 4FRONT-2). — Phase III results are the most significant clinical catalysts for biotech valuations as they determine potential FDA approval and commercial viability.
+0.60The company expects to start a trial for diabetic macular edema (DME) with 4D-150 later this year. — Expansion into a second major indication increases the total addressable market and validates the platform's versatility.
+0.30Which stocks this story touches
The company is presenting its gene therapy platform and progressing its lead program into Phase III trials.
Continue reading
6 related stories
Top 3 movers · tap to explore
Goldman Sachs is mentioned as the host of the healthcare conference.
Go deeper
You just saw which tickers this one story hits. A free account turns that into a standing screen: the movers delivered on schedule, before the chart catches up.
On this page · free
In the platform
Free account, 30 seconds. No credit card. Covers all 10 tickers this story moves.
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Screener bridge
GS showed up in this week’s NIS Momentum screen.
Get the full NIS Momentum results every Friday at 4PM ET — free via email or Telegram.
Seeking Alpha
5h ago
